Response–durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis
BJU International · 09.11.2026
DOI: 10.1111/bju.70533 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 09.11.2026. Verfasst von Ryunosuke Nakagawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine whether response durability refines the clinical interpretation of objective response (OR) to erdafitinib in patients with fibroblast growth factor receptor (FGFR)‐altered metastatic urothelial carcinoma. Patients and Methods This post hoc exploratory analysis used de‐identified individual participant‐level data from THOR trial Cohort 1 (ClinicalTrials.gov identifier: NCT03390504) The safety population included 247 patients treated with erdafitinib ( n = 135) or chemotherapy ( n = 112). Response–durability phenotypes were defined by integrating best overall response with a 6‐month progression‐free survival threshold: durable OR, durable disease control, non‐durable OR, and limited benefit. Phenotype distributions were compared between treatment arms. Overall survival (OS) was evaluated using Kaplan–Meier and Cox analyses, including 6‐month landmark analyses to reduce guarantee‐time bias.
Results
Erdafitinib shifted patients toward more favourable response–durability phenotypes compared with chemotherapy. Limited benefit was less frequent with erdafitinib than with chemotherapy (45.9% vs 75.9%; P < 0.001), whereas OR phenotypes were more common. In erdafitinib‐treated patients, 6‐month landmark OS differed significantly across phenotypes ( P < 0.001). Durable benefit was associated with longer landmark OS than non‐durable benefit (non‐durable vs durable benefit: hazard ratio [HR] 4.09, 95% confidence interval [CI] 2.24–7.49). Among objective responders, non‐durable OR was associated with substantially worse landmark OS than durable OR (HR 8.71, 95% CI 3.30–22.96).
Conclusions
In patients with FGFR‐altered metastatic urothelial carcinoma treated with erdafitinib, Response Evaluation Criteria in Solid Tumours (RECIST) OR alone did not fully capture clinically meaningful benefit. Incorporating response durability provided stronger survival stratification and may improve the interpretation of treatment benefit after FGFR‐targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
ORCID-Profile: Ryunosuke Nakagawa, Tomohiro Hori, Taiki Kamijima, Suguru Kadomoto, Tomoyuki Makino, Renato Naito, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara, Kouji Izumi, Atsushi Mizokami
Zitieren
APA
Nakagawa, R., Hori, T., Kamijima, T., Kadomoto, S., Makino, T., Naito, R., Iwamoto, H., Yaegashi, H., Shigehara, K., Nohara, T., Izumi, K., & Mizokami, A. (2026). Response–durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis. BJU International. https://doi.org/10.1111/bju.70533
Vancouver
Nakagawa R, Hori T, Kamijima T, Kadomoto S, Makino T, Naito R, et al. Response–durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis. BJU International. 2026. doi:10.1111/bju.70533
BibTeX
@article{Nakagawa2026,
author = {Nakagawa, Ryunosuke and Hori, Tomohiro and Kamijima, Taiki and Kadomoto, Suguru and Makino, Tomoyuki and Naito, Renato and Iwamoto, Hiroaki and Yaegashi, Hiroshi and Shigehara, Kazuyoshi and Nohara, Takahiro and Izumi, Kouji and Mizokami, Atsushi},
title = {Response–durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70533}
}
EUVIMED